<p>Sicart Associates LLC 在最近向證券交易委員會的披露中表示，在第三季度將其在 Guardant Health, Inc. (NASDAQ:GH - 免費報告) 的持股比例增加了 39.1%。該公司在本季度額外購買了 64,628 股後，持有該公司 230,083 股股票。Guardant Health 佔 Sicart Associates LLC 投資組合的 3.9%，是其第五大持倉。截至最近向證券交易委員會的備案，Sicart Associates LLC 持有的 Guardant Health 股票約佔 0.18%，價值 14,376,000 美元。</p>
<p>獲取 <strong>Guardant Health</strong> 警報：</p>
<ul>
<li>4 只醫療保健股票大幅上漲——還有更多上漲空間</li>
</ul>
<p>其他幾家對沖基金最近也調整了對該股票的持有。Osaic Holdings Inc. 在第二季度將其在 Guardant Health 的持股比例提高了 118.6%。Osaic Holdings Inc. 目前持有 29,561 股該公司股票，價值 1,538,000 美元，此前在上個季度額外購買了 16,039 股。懷俄明州州政府在第二季度獲得了 Guardant Health 的新頭寸，價值約 567,000 美元。Castleark Management LLC 在第二季度購買了 Guardant Health 的新頭寸，價值約 6,326,000 美元。Nikko Asset Management Americas Inc. 在第二季度將其在 Guardant Health 的持股比例提高了 49.6%。Nikko Asset Management Americas Inc. 目前持有 2,030,428 股該公司股票，價值 105,623,000 美元，此前在上個季度額外購買了 673,438 股。最後，加拿大人壽保險公司在第二季度將其在 Guardant Health 的持股比例提高了 8.1%。加拿大人壽保險公司目前持有 32,485 股該公司股票，價值 1,694,000 美元，此前在上個季度額外購買了 2,421 股。機構投資者和對沖基金持有該公司 92.60% 的股票。</p>
<h2>Guardant Health 股票下跌 2.6%</h2>
<p>GH 股票週三開盤價為 100.00 美元。Guardant Health, Inc. 的 52 周低點為 29.91 美元，52 周高點為 112.43 美元。該股票的市值為 126 億美元，市盈率為 -31.15，貝塔值為 1.58。該公司的 50 日移動平均線為 90.23 美元，200 日移動平均線為 66.58 美元。</p>
<ul>
<li>解讀顛覆：深入瞭解 Cathie Wood 的最新投資</li>
</ul>
<p>Guardant Health (NASDAQ:GH - 獲取免費報告) 最近在 10 月 29 日發佈了季度財報。該公司報告每股收益 (EPS) 為 -0.39 美元，超出分析師一致預期的 -0.48 美元，超出幅度為 0.09 美元。該公司本季度的收入同比增長 38.5%。去年同期，該公司每股收益為 -0.88 美元。整體來看，賣方分析師預計 Guardant Health, Inc. 本年度將發佈 -2.9 的每股收益。</p>
<h2>分析師升級與降級</h2>
<p>GH 最近成為幾份研究報告的主題。Guggenheim 將 Guardant Health 的目標價從 56.00 美元上調至 67.00 美元，並在 9 月 25 日的研究報告中給予該股票 &#34;買入&#34; 評級。摩根大通將 Guardant Health 的目標價從 90.00 美元上調至 120.00 美元，並在週一的研究報告中給予該股票 &#34;增持&#34; 評級。花旗集團將 Guardant Health 的目標價從 100.00 美元上調至 135.00 美元，並在 12 月 11 日的報告中給予該公司 &#34;買入&#34; 評級。瑞銀集團將 Guardant Health 的目標價從 80.00 美元上調至 110.00 美元，並在 10 月 30 日的報告中給予該股票 &#34;買入&#34; 評級。最後，TD Cowen 將 Guardant Health 的目標價從 63.00 美元上調至 72.00 美元，並在 9 月 25 日的報告中給予該公司 &#34;買入&#34; 評級。23 位股票研究分析師對該股票給予了買入評級，1 位分析師對該公司給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;適度買入&#34;，平均目標價為 94.57 美元。</p>
<ul>
<li>3 只快速增長的股票分析師預計價格翻倍</li>
</ul>
<p><strong>查看我們關於 Guardant Health 的最新研究報告</strong></p>
<h2>Guardant Health 內部交易</h2>
<p>在其他 Guardant Health 的新聞中，首席財務官 Michael Brian Bell 於 12 月 5 日星期五出售了 80,362 股該公司的股票。該股票以平均價格 103.14 美元出售，總交易額為 8,288,536.68 美元。交易後，首席財務官直接持有該公司 28,052 股股票，價值 2,893,283.28 美元。這代表其持股比例減少了 74.13%。該交易已在向證券交易委員會提交的文件中披露，相關文件可在 SEC 網站上獲取。此外，首席技術官 Darya Chudova 於 12 月 8 日星期一出售了 13,664 股該公司的股票。該股票以平均價格 105.04 美元出售，總價值為 1,435,266.56 美元。交易後，首席技術官持有該公司 54,480 股股票，價值約 5,722,579.20 美元。這代表其持股比例減少了 20.05%。該交易的披露信息可在 SEC 文件中找到。內部人士在過去三個月內出售了價值 34,526,719 美元的 330,531 股公司股票。公司內部人士持有該公司 6.10% 的股票。</p>
<h2>Guardant Health 公司簡介</h2>
<p>(免費報告)</p>
<p>Guardant Health, Inc.是一家精準腫瘤學公司，在美國和國際上提供血液和組織檢測、數據集和分析。該公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 測試；Guardant360 響應測試；Guardant360 TissueNext 測試；GuardantINFINITY 測試；GuardantConnect，這是一個集成的軟件解決方案，旨在幫助臨牀和生物製藥客户將接受檢測的患者與具有潛在相關臨牀研究的可操作性變更連接起來；GuardantOMNI 測試用於晚期癌症；以及 GuardantINFORM，這是一個用於腫瘤演變和治療耐藥性的計算機模擬研究平台，適用於各種生物標誌物驅動的癌症。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票超過 Guardant Health</li>
<li>什麼是內幕交易？你可以從內幕交易中學到什麼</li>
<li>AI 芯片離不開這兩家被低估的科技巨頭</li>
<li>3 只家居改善股票可以升級你的投資組合</li>
<li>為什麼台灣半導體的 6.5% 下跌可能是一個聰明的買入機會</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>RTX 因國防訂單激增而飆升至歷史新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
<p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Guardant Health 並不在名單上。</p>
<p>雖然 Guardant Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Sicart Associates LLC 在第三季度將其在 Guardant Health, Inc. 的持股增加了 39.1%，目前擁有 230,083 股，價值 1438 萬美元。分析師們提高了對 Guardant Health 的目標價格，Guggenheim、摩根大通、花旗集團、瑞士銀行和 TD Cowen 均給予 “買入” 評級。該股票的平均評級為 “適度買入”，目標價格為 94.57 美元。首席財務官 Michael Bell 出售了 80,362 股，減少了 74.13% 的持股</p>

<p>Sicart Associates LLC grew its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 39.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 230,083 shares of the company's stock after purchasing an additional 64,628 shares during the quarter. Guardant Health makes up 3.9% of Sicart Associates LLC's holdings, making the stock its 5th biggest position. Sicart Associates LLC owned about 0.18% of Guardant Health worth $14,376,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Sicart Associates LLC 在最近向證券交易委員會的披露中表示，在第三季度將其在 Guardant Health, Inc. (NASDAQ:GH - 免費報告) 的持股比例增加了 39.1%。該公司在本季度額外購買了 64,628 股後，持有該公司 230,083 股股票。Guardant Health 佔 Sicart Associates LLC 投資組合的 3.9%，是其第五大持倉。截至最近向證券交易委員會的備案，Sicart Associates LLC 持有的 Guardant Health 股票約佔 0.18%，價值 14,376,000 美元。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Guardant Health</strong> 警報：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只醫療保健股票大幅上漲——還有更多上漲空間</li>
</ul>
</div><p>Several other hedge funds have also recently modified their holdings of the stock. Osaic Holdings Inc. lifted its stake in Guardant Health by 118.6% in the 2nd quarter. Osaic Holdings Inc. now owns 29,561 shares of the company's stock valued at $1,538,000 after buying an additional 16,039 shares in the last quarter. State of Wyoming acquired a new position in shares of Guardant Health during the second quarter valued at approximately $567,000. Castleark Management LLC purchased a new position in shares of Guardant Health in the second quarter valued at approximately $6,326,000. Nikko Asset Management Americas Inc. boosted its stake in shares of Guardant Health by 49.6% in the second quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company's stock worth $105,623,000 after acquiring an additional 673,438 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of Guardant Health by 8.1% during the second quarter. CANADA LIFE ASSURANCE Co now owns 32,485 shares of the company's stock worth $1,694,000 after purchasing an additional 2,421 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也調整了對該股票的持有。Osaic Holdings Inc. 在第二季度將其在 Guardant Health 的持股比例提高了 118.6%。Osaic Holdings Inc. 目前持有 29,561 股該公司股票，價值 1,538,000 美元，此前在上個季度額外購買了 16,039 股。懷俄明州州政府在第二季度獲得了 Guardant Health 的新頭寸，價值約 567,000 美元。Castleark Management LLC 在第二季度購買了 Guardant Health 的新頭寸，價值約 6,326,000 美元。Nikko Asset Management Americas Inc. 在第二季度將其在 Guardant Health 的持股比例提高了 49.6%。Nikko Asset Management Americas Inc. 目前持有 2,030,428 股該公司股票，價值 105,623,000 美元，此前在上個季度額外購買了 673,438 股。最後，加拿大人壽保險公司在第二季度將其在 Guardant Health 的持股比例提高了 8.1%。加拿大人壽保險公司目前持有 32,485 股該公司股票，價值 1,694,000 美元，此前在上個季度額外購買了 2,421 股。機構投資者和對沖基金持有該公司 92.60% 的股票。</p>
</div><h2>Guardant Health Stock Down 2.6%</h2>
<div class="lb-trans"><h2>Guardant Health 股票下跌 2.6%</h2>
</div><p>GH stock opened at $100.00 on Wednesday. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43. The stock has a market cap of $12.60 billion, a price-to-earnings ratio of -31.15 and a beta of 1.58. The business has a fifty day moving average of $90.23 and a two-hundred day moving average of $66.58.</p>
<div class="lb-trans"><p>GH 股票週三開盤價為 100.00 美元。Guardant Health, Inc. 的 52 周低點為 29.91 美元，52 周高點為 112.43 美元。該股票的市值為 126 億美元，市盈率為 -31.15，貝塔值為 1.58。該公司的 50 日移動平均線為 90.23 美元，200 日移動平均線為 66.58 美元。</p>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解讀顛覆：深入瞭解 Cathie Wood 的最新投資</li>
</ul>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. The business's revenue for the quarter was up 38.5% on a year-over-year basis. During the same period last year, the company earned ($0.88) EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.</p>
<div class="lb-trans"><p>Guardant Health (NASDAQ:GH - 獲取免費報告) 最近在 10 月 29 日發佈了季度財報。該公司報告每股收益 (EPS) 為 -0.39 美元，超出分析師一致預期的 -0.48 美元，超出幅度為 0.09 美元。該公司本季度的收入同比增長 38.5%。去年同期，該公司每股收益為 -0.88 美元。整體來看，賣方分析師預計 Guardant Health, Inc. 本年度將發佈 -2.9 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級與降級</h2>
</div><p>GH has been the topic of several recent research reports. Guggenheim lifted their target price on shares of Guardant Health from $56.00 to $67.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, September 25th. JPMorgan Chase &amp; Co. boosted their price target on shares of Guardant Health from $90.00 to $120.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday. Citigroup increased their price objective on shares of Guardant Health from $100.00 to $135.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 11th. UBS Group boosted their target price on Guardant Health from $80.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 30th. Finally, TD Cowen increased their price target on Guardant Health from $63.00 to $72.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $94.57.</p>
<div class="lb-trans"><p>GH 最近成為幾份研究報告的主題。Guggenheim 將 Guardant Health 的目標價從 56.00 美元上調至 67.00 美元，並在 9 月 25 日的研究報告中給予該股票 &#34;買入&#34; 評級。摩根大通將 Guardant Health 的目標價從 90.00 美元上調至 120.00 美元，並在週一的研究報告中給予該股票 &#34;增持&#34; 評級。花旗集團將 Guardant Health 的目標價從 100.00 美元上調至 135.00 美元，並在 12 月 11 日的報告中給予該公司 &#34;買入&#34; 評級。瑞銀集團將 Guardant Health 的目標價從 80.00 美元上調至 110.00 美元，並在 10 月 30 日的報告中給予該股票 &#34;買入&#34; 評級。最後，TD Cowen 將 Guardant Health 的目標價從 63.00 美元上調至 72.00 美元，並在 9 月 25 日的報告中給予該公司 &#34;買入&#34; 評級。23 位股票研究分析師對該股票給予了買入評級，1 位分析師對該公司給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;適度買入&#34;，平均目標價為 94.57 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增長的股票分析師預計價格翻倍</li>
</ul>
</div><p><strong>View Our Latest Research Report on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Guardant Health 的最新研究報告</strong></p>
</div><h2>Insider Transactions at Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 內部交易</h2>
</div><p>In other Guardant Health news, CFO Michael Brian Bell sold 80,362 shares of the company's stock in a transaction on Friday, December 5th. The stock was sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the transaction, the chief financial officer directly owned 28,052 shares in the company, valued at $2,893,283.28. This represents a 74.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CTO Darya Chudova sold 13,664 shares of the firm's stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.04, for a total value of $1,435,266.56. Following the transaction, the chief technology officer owned 54,480 shares of the company's stock, valued at approximately $5,722,579.20. This represents a 20.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 330,531 shares of company stock worth $34,526,719 in the last three months. Company insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Guardant Health 的新聞中，首席財務官 Michael Brian Bell 於 12 月 5 日星期五出售了 80,362 股該公司的股票。該股票以平均價格 103.14 美元出售，總交易額為 8,288,536.68 美元。交易後，首席財務官直接持有該公司 28,052 股股票，價值 2,893,283.28 美元。這代表其持股比例減少了 74.13%。該交易已在向證券交易委員會提交的文件中披露，相關文件可在 SEC 網站上獲取。此外，首席技術官 Darya Chudova 於 12 月 8 日星期一出售了 13,664 股該公司的股票。該股票以平均價格 105.04 美元出售，總價值為 1,435,266.56 美元。交易後，首席技術官持有該公司 54,480 股股票，價值約 5,722,579.20 美元。這代表其持股比例減少了 20.05%。該交易的披露信息可在 SEC 文件中找到。內部人士在過去三個月內出售了價值 34,526,719 美元的 330,531 股公司股票。公司內部人士持有該公司 6.10% 的股票。</p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p>
<div class="lb-trans"><p>Guardant Health, Inc.是一家精準腫瘤學公司，在美國和國際上提供血液和組織檢測、數據集和分析。該公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 測試；Guardant360 響應測試；Guardant360 TissueNext 測試；GuardantINFINITY 測試；GuardantConnect，這是一個集成的軟件解決方案，旨在幫助臨牀和生物製藥客户將接受檢測的患者與具有潛在相關臨牀研究的可操作性變更連接起來；GuardantOMNI 測試用於晚期癌症；以及 GuardantINFORM，這是一個用於腫瘤演變和治療耐藥性的計算機模擬研究平台，適用於各種生物標誌物驅動的癌症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>What is Insider Trading? What You Can Learn from Insider Trading</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Guardant Health</li>
<li>什麼是內幕交易？你可以從內幕交易中學到什麼</li>
<li>AI 芯片離不開這兩家被低估的科技巨頭</li>
<li>3 只家居改善股票可以升級你的投資組合</li>
<li>為什麼台灣半導體的 6.5% 下跌可能是一個聰明的買入機會</li>
<li>最活躍的股票：美元交易量與股數交易量</li>
<li>RTX 因國防訂單激增而飆升至歷史新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Guardant Health 並不在名單上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Guardant Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Guardant Health, Inc. $GH 的持股量被 Sicart Associates LLC 增加